HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

N Finer Selected Research

sibutramine (Meridia)

5/2015Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.
9/2014Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease.
6/2014Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial.
3/2014Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients.
9/2012Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes.
6/2012Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
1/2010Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
3/2009Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
6/2008Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
3/2006Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


N Finer Research Topics

Disease

26Weight Loss (Weight Reduction)
08/2018 - 03/2000
13Obesity
08/2018 - 03/2000
10Overweight
05/2015 - 04/2000
8Body Weight (Weight, Body)
05/2014 - 03/2000
6Type 2 Diabetes Mellitus (MODY)
01/2018 - 04/2000
3Cardiovascular Diseases (Cardiovascular Disease)
06/2014 - 06/2012
2Nausea
05/2014 - 06/2012
2Vomiting
05/2014 - 06/2012
2Weight Gain
03/2009 - 03/2008
2Insulin Resistance
07/2005 - 11/2002
1Chronic Disease (Chronic Diseases)
01/2018
1Prader-Willi Syndrome (Syndrome, Prader-Willi)
02/2016
1Hyperphagia (Overeating)
02/2016
1Myocardial Infarction
03/2014
1Anemia
03/2014
1Heart Arrest (Cardiac Arrest)
03/2014
1Inflammation (Inflammations)
03/2014
1Stroke (Strokes)
03/2014
1Metabolic Syndrome (Dysmetabolic Syndrome X)
06/2012
1Prediabetic State (Prediabetes)
06/2012
1Airway Obstruction (Choking)
10/2010
1Abdominal Obesity
12/2008
1Birth Weight (Birth Weights)
11/2006
1Injection Site Reaction
11/2005
1Morbid Obesity
02/2005
1Familial Breast Cancer
08/2003
1Breast Neoplasms (Breast Cancer)
08/2003
1Hypertension (High Blood Pressure)
12/2002
1Drug-Related Side Effects and Adverse Reactions
12/2002
1Cross Infection (Nosocomial Infection)
04/2001
1Sepsis (Septicemia)
04/2001
1Coronary Disease (Coronary Heart Disease)
12/2000

Drug/Important Bio-Agent (IBA)

17sibutramine (Meridia)FDA Link
05/2015 - 04/2000
4Glucose (Dextrose)FDA LinkGeneric
10/2016 - 03/2000
4Orlistat (Xenical)FDA Link
05/2014 - 03/2000
4Pharmaceutical PreparationsIBA
06/2012 - 12/2002
4Insulin (Novolin)FDA Link
01/2010 - 03/2000
3Triglycerides (Triacylglycerol)IBA
10/2016 - 12/2000
3LipidsIBA
06/2012 - 03/2000
2LDL CholesterolIBA
10/2016 - 12/2000
2LiraglutideFDA Link
05/2014 - 06/2012
2Anti-Obesity Agents (Antiobesity Drugs)IBA
04/2011 - 03/2006
1BilirubinIBA
06/2014
1Hemoglobins (Hemoglobin)IBA
03/2014
1CreatinineIBA
03/2014
1IronIBA
03/2014
1AndrogensIBA
06/2013
1Glucagon-Like Peptide 1 (GLP 1)IBA
06/2012
1Oxygen (Dioxygen)IBA
10/2010
1Antihypertensive Agents (Antihypertensives)IBA
03/2009
110-N-nonylacridinium orange (NAO)IBA
12/2008
1antineoplaston A10 (A 10)IBA
03/2008
1Surface-Active Agents (Surfactants)IBA
11/2006
1LeptinIBA
11/2005
1recombinant methionyl human leptinIBA
11/2005
1CholesterolIBA
07/2005
1BariumIBA
02/2005
1Dietary Fats (Dietary Fat)IBA
12/2002
1Proteins (Proteins, Gene)FDA Link
11/2001
1CarbohydratesIBA
11/2001
1CoagulaseIBA
04/2001
1HDL CholesterolIBA
12/2000
1VLDL CholesterolIBA
12/2000
1AminesIBA
12/2000
1beta Carotene (Betacarotene)FDA Link
03/2000
1VitaminsIBA
03/2000
1Lipase (Acid Lipase)FDA Link
03/2000

Therapy/Procedure

2Gastric Bypass (Roux-en-Y Gastric Bypass)
01/2018 - 02/2005
2Drug Therapy (Chemotherapy)
04/2011 - 12/2002
2Therapeutics
12/2001 - 12/2000
2Caloric Restriction
11/2001 - 12/2000
1Contraceptive Devices (Contraceptive Device)
08/2018
1Transition to Adult Care
01/2018
1Gastrectomy
01/2018
1Vagus Nerve Stimulation
02/2016
1Continuous Positive Airway Pressure
11/2006
1Gastroplasty (Vertical-Banded Gastroplasty)
02/2005
1Biliopancreatic Diversion
02/2005
1Replantation
08/2003
1Prophylactic Mastectomy
08/2003
1Subcutaneous Mastectomy
08/2003
1Obesity Management
11/2002
1Fat-Restricted Diet (Diet, Fat Restricted)
11/2001
1Catheters
04/2001